MétaCan
Menu
Back to cohort
Record W4413942153 · doi:10.1002/cac2.70058

Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by <i>UGT1A1</i> status in patients with locally advanced rectal cancer: 5‐year update of the CinClare trial

2025· article· en· W4413942153 on OpenAlex

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

affAt least one author lists a Canadian institution in the pinned OpenAlex snapshot.

Bibliographic record

VenueCancer Communications · 2025
Typearticle
Languageen
FieldMedicine
TopicColorectal Cancer Treatments and Studies
Canadian institutionsCAE (Canada)
FundersKey Research and Development Program of Zhejiang ProvinceNational Health Commission of the People's Republic of ChinaNational Natural Science Foundation of China
KeywordsCapecitabineIrinotecanColorectal cancerMedicineOncologyInternal medicineChemoradiotherapyNeoadjuvant therapyCancer

Abstract

fetched live from OpenAlex

Abstract Background The optimal regimen and chemotherapy intensity are still under investigation for neoadjuvant treatment of locally advanced rectal cancer (LARC). The CinClare trial has demonstrated improved pathologic complete response (pCR) with the addition of irinotecan to neoadjuvant chemoradiotherapy (CRT) guided by uridine diphosphate glucuronosyltransferase 1A1 ( UGT1A1) genotype in LARC. Here, we report the 5‐year follow‐up outcomes of the CinClare study. Methods From November 2015 to December 2017, this randomized, open‐label, multicenter, phase III trial enrolled 360 patients with LARC and assigned them in a 1:1 ratio to CapIriRT (radiation with capecitabine combined with irinotecan followed by irinotecan and capecitabine) or CapRT (radiation with concurrent capecitabine followed by oxaliplatin and capecitabine). Irinotecan dosing was guided by UGT1A1 genotype (80 mg/m 2 for *1/*1 and 65 mg/m 2 for *1/*28 ). The endpoints, including local control (LC), distant metastasis‐free survival (DMFS), disease‐free survival (DFS), and overall survival (OS), were analyzed using the log‐rank test, Cox proportional hazards regression and restricted mean survival time (RMST) test at the data cut‐off date of June 2023. Results With a median follow‐up of 60 months, the CapIriRT group showed numerically higher 5‐year LC (95.6% vs. 93.9%), 5‐year DMFS (83.9% vs. 77.9%), 5‐year DFS (77.7% vs. 70.6%), and 5‐year OS rates (82.9% vs. 76.1%) than the CapRT group. Further RMST test also showed a statistically significant difference in DFS ( P &lt; 0.05) and a borderline difference in OS ( P = 0.050). Among the UGT1A1 *1/*1 population, the CapIriRT group had significantly improved 5‐year rates of DMFS, DFS, and OS (all P &lt; 0.05). Patients achieving pCR also had significantly longer DFS and OS compared to non‐pCR patients ( P &lt; 0.05). Conclusions The addition of irinotecan guided by UGT1A1 genotype to a standard capecitabine‐based scheme brings clinical benefits with improved LC, DMFS, DFS, and OS. Patients with the UGT1A1 *1/*1 genotype derived notable benefit from irinotecan, with improved survival outcomes. Achievement of pCR is crucial as it is associated with improved long‐term survival. These findings support the integration of genomic testing into clinical practice to achieve a personalized irinotecan dosing regimen, which can optimize efficacy and safety. Trial registration ClinicalTrials.gov (NCT02605265).

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.128
Threshold uncertainty score0.613

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.010
GPT teacher head0.291
Teacher spread0.281 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it